Compare NKX & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NKX | CADL |
|---|---|---|
| Founded | 2002 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 664.8M | 694.6M |
| IPO Year | N/A | 2021 |
| Metric | NKX | CADL |
|---|---|---|
| Price | $12.40 | $10.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 145.3K | ★ 1.1M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 4.37% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.67 | $4.35 |
| 52 Week High | $13.20 | $11.36 |
| Indicator | NKX | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 60.63 |
| Support Level | $12.27 | $9.18 |
| Resistance Level | $12.50 | $11.36 |
| Average True Range (ATR) | 0.09 | 0.47 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 97.50 | 87.00 |
Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.